Britain and America have agreed to a important commercial pact that will keep zero levies on British medicine products going into the US market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to increase expenditure on drugs through the public health system. This pledge ensures that tariffs on these crucial exports will stay at nothing for a timeframe of the next three years.
This agreement comes after previous threats to hike import taxes on patented drug imports, with figures discussed as high as double the cost.
"This deal with the United Kingdom reinforces the worldwide climate for cutting-edge drugs and brings much-needed fairness to American-British pharmaceutical trade," a release said.
Economic Significance
Drugs constitute one of the the United Kingdom's largest exports to the United States, which is clearly the largest buyer for major British pharmaceutical firms.
Statistics show that in the 12 months leading up to the third quarter, the UK sold pharmaceutical products valued at £11.1bn to the US. This value accounted for a significant portion of total UK exports in that span.
"This agreement safeguards jobs, increases funding and facilitates the UK to emerge as a international leader for medical research," a government official commented.
Key British Pledges
The deal entails several key commitments from the British government:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new medicines to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to double total NHS spending on treatments from 0.3% of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be limited at 15%. Last year, refunds topped 20%.
Broader Context
The pact takes place against a ongoing dispute between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
The disagreement were intensified by assertions that American consumers were charged several times more for the identical medicines than patients in the other developed nations.
In recent months, several large drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar investments have been pledged toward American operations.
One official acknowledged that the NHS had to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a share of its total funding over the last ten years.
